I'm not suggesting that NEU would have any intention of trashing the ACAD deal.
However, the presence of 2591 in NEU's portfolio is a long term threat to the profitability of trofinetide (from ACAD's perspective).
When ACAD committed to the North America deal, and subsequently failed to wrap up the ROW rights, they have left themselves exposed. While NEU has said they won't target Rett And Fragile X patients, if and when 2591 is approved, it is almost impossible to expect that whoever might take NEU out would feel similarly inclined.
The pressure is well and truly on ACAD to come up with an buyout offer that NEU cannot ignore.
Ann: Validation for NNZ-2591 neurodevelopmental disorder pipeline, page-80
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$12.85 |
Change
-0.110(0.85%) |
Mkt cap ! $1.598B | |||
| Open | High | Low | Value | Volume |
| $12.82 | $13.05 | $12.53 | $6.559M | 511.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1657 | $12.83 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.85 | 6303 | 1 |
View Market Depth
| Last trade - 16.10pm 17/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |